身体铁指数在评价孕产妇铁不足中的应用及多糖铁间断性口服效果评价研究

注册号:

Registration number:

ChiCTR2400079913 

最近更新日期:

Date of Last Refreshed on:

2024-01-16 10:13:57 

注册时间:

Date of Registration:

2024-01-16 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

身体铁指数在评价孕产妇铁不足中的应用及多糖铁间断性口服效果评价研究

Public title:

Application of body iron index in the evaluation of iron deficiency in pregnant women and evaluation of intermittent oral administration of polysaccharide iron

注册题目简写:

English Acronym:

研究课题的正式科学名称:

身体铁指数在评价孕产妇铁不足中的应用及多糖铁间断性口服效果评价研究

Scientific title:

Application of body iron index in the evaluation of iron deficiency in pregnant women and evaluation of intermittent oral administration of polysaccharide iron

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

孙莉 

研究负责人:

陈洁 

Applicant:

Sun Li 

Study leader:

Chen Jie 

申请注册联系人电话:

Applicant telephone:

+86 156 6583 5121

研究负责人电话:

Study leader's
telephone:

+86 186 1565 6606

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

bydxna@163.com

研究负责人电子邮件:

Study leader's E-mail:

77chenjie@sdu.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

山东省济南市历下区文化西路44号

研究负责人通讯地址:

山东省济南市历下区文化西路44号

Applicant address:

44 Wenhua West Road, Lixia District, Jinan City, Shandong Province

Study leader's address:

44 Wenhua West Road, Lixia District, Jinan City, Shandong Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

山东大学公共卫生学院

Applicant's institution:

Shandong University School of Public Health

研究负责人所在单位:

山东大学公共卫生学院

Affiliation of the Leader:

Shandong University School of Public Health

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

LL20231102

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

山东大学公共卫生伦理学委员会

Name of the ethic committee:

Shandong University Public Health Ethics Committee

伦理委员会批准日期:

Date of approved by ethic committee:

2023-11-24 00:00:00

伦理委员会联系人:

孙强

Contact Name of the ethic committee:

Sun Qiang

伦理委员会联系地址:

山东省济南市历下区文化西路44号

Contact Address of the ethic committee:

44 Wenhua West Road, Lixia District, Jinan City, Shandong Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 88382376

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

山东大学公共卫生学院

Primary sponsor:

Shandong University School of Public Health

研究实施负责(组长)单位地址:

山东省济南市历下区文化西路44号

Primary sponsor's address:

44 Wenhua West Road, Lixia District, Jinan City, Shandong Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

山东

市(区县):

济南

Country:

China

Province:

Shandong

City:

Jinan

单位(医院):

山东大学公共卫生学院

具体地址:

山东省济南市历下区文化西路44号

Institution
hospital:

Shandong University School of Public Health

Address:

44 Wenhua West Road, Lixia District, Jinan City, Shandong Province

经费或物资来源:

Source(s) of funding:

none

研究疾病:

缺铁性贫血  

Target disease:

iron deficiency anemia

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

1.孕早期进行铁缺乏筛查,是否为更佳的铁缺乏筛查窗口期。 2.对铁不足孕产妇进行铁剂补充干预是否可以更好的预防缺铁性贫血的发生。 3.铁剂的隔日补充是否有更好的依从性和更少的副作用,但同样具有和连续性补充一样的补铁效果。  

Objectives of Study:

1. Whether screening for iron deficiency in the first trimester is a better window period for iron deficiency screening. 2. Whether iron supplement intervention for iron-deficient pregnant women can better prevent the occurrence of iron-deficiency anemia. 3. Does every other day supplementation of iron have better compliance and fewer side effects, but also have the same iron supplementation effect as continuous supplementation

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.无法按医嘱服药、产检或在本院分娩;2.血液疾患如地中海贫血、溶血性贫血、再生障碍性贫血等;3.孕前3个月至调查时间内参加了任何1项药物或营养临床试验者;4.膳食补充剂服用信息不详;5.既往患有糖尿病、感染性疾病、多囊卵巢综合征、甲状腺疾病或其他系统性疾病(包括心脑血管疾病、神经系统疾病、免疫系统疾病)

Exclusion criteria:

1. Failure to take medication, take a prenatal examination or give birth in the hospital as prescribed; 2. Blood disorders such as thalassemia, hemolytic anemia, aplastic anemia, etc.; 3. Participants who participated in any drug or nutrition clinical trial from 3 months before pregnancy to the survey time; 4. Dietary supplement consumption information is unknown; 5. Previous diabetes, infectious diseases, polycystic ovary syndrome, thyroid disease or other systemic diseases (including cardiovascular and cerebrovascular diseases, neurological diseases, immune system diseases)

研究实施时间:

Study execute time:

From 2024-01-20 00:00:00 To 2025-03-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-01-20 00:00:00 To 2024-09-01 00:00:00

干预措施:

Interventions:

组别:

铁缺乏A-1组

样本量:

34

Group:

Iron deficiency Group A-1

Sample size:

干预措施:

间隔服用多糖铁复合物胶囊

干预措施代码:

Intervention:

Taking iron polysaccharide complex capsules at intervals

Intervention code:

组别:

铁缺乏A-2组

样本量:

34

Group:

Iron deficiency Group A-2

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

铁缺乏B-1组

样本量:

34

Group:

Iron deficiency Group B-1

Sample size:

干预措施:

间隔服用多糖铁复合物胶囊

干预措施代码:

Intervention:

Taking iron polysaccharide complex capsules at intervals

Intervention code:

组别:

铁缺乏B-2组

样本量:

34

Group:

Iron deficiency Group B-2

Sample size:

干预措施:

连续服用多糖铁复合物胶囊

干预措施代码:

Intervention:

Taking polysaccharide iron complex capsules continuously

Intervention code:

组别:

轻度贫血组1

样本量:

34

Group:

Mild anemia group 1

Sample size:

干预措施:

间隔服用多糖铁复合物胶囊

干预措施代码:

Intervention:

Taking iron polysaccharide complex capsules at intervals

Intervention code:

组别:

轻度贫血组2

样本量:

34

Group:

Mild anemia group 2

Sample size:

干预措施:

连续服用多糖铁复合物胶囊

干预措施代码:

Intervention:

Taking polysaccharide iron complex capsules continuously

Intervention code:

组别:

对照组

样本量:

68

Group:

Control group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

山东 

市(区县):

济南 

Country:

China

Province:

Shandong

City:

Jinan

单位(医院):

山东大学第二医院 

单位级别:

三甲 

Institution
hospital:

The Second Hospital of Shandong University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

山东 

市(区县):

济南 

Country:

China

Province:

Shandong

City:

Jinan

单位(医院):

济南市妇幼保健院 

单位级别:

三甲 

Institution
hospital:

Jinan maternal and child Health Care Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

山东 

市(区县):

济南 

Country:

China

Province:

Shandong

City:

Jinan

单位(医院):

山东大学齐鲁医院 

单位级别:

三甲 

Institution
hospital:

Qilu HospitalO f Shandong University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

铁缺乏发生率

指标类型:

主要指标

Outcome:

Incidence rate of iron deficiency

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

缺铁性贫血发生率

指标类型:

次要指标

Outcome:

Incidence rate of Iron deficiency anemia

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

不良妊娠结局

指标类型:

次要指标

Outcome:

adverse pregnancy outcomes

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 20 years
最大 Max age 55 years

性别:

女性

Gender:

Female

随机方法(请说明由何人用什么方法产生随机序列):

根据入选患者编号01-68,采用随机数字表,选取68个数字,从大到小进行排列,前34个为不干预组或连续服药组,后34个为间隔服药组。

Randomization Procedure (please state who generates the random number sequence and by what method):

According to the number of enrolled patients 01-68, a random number table was used to select 68 numbers, which were arranged from largest to smallest. The first 34 were non-intervention group or continuous medication group, and the last 34 were interval medication group.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

None

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

不共享原始数据

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Do not share raw data

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表和调查问卷

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF and questionnaires

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2024-01-16 10:13:53